SCHEMBL9103232

SCHEMBL9103232

CCCNc1nc(NCCC)nc(N(OCc2ccccc2)C(C)C)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.42
BCHE P06276 3/20 0.42
ACHE P22303 3/20 0.42
ALDH1A1 P00352 2/20 0.40
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HTR7 P34969 2/20 0.39
PKM P14618 1/20 0.39
RAD52 P43351 1/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
KCNH3 Q9ULD8 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
CYP1A2 P05177 2/20 0.37
CYP2C19 P33261 2/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL9106850 0.94 CA1 (0.40) APPBCHEACHEALDH1A1TP53
SCHEMBL9106762 0.83 APP (0.48) APPBCHEACHEALDH1A1TP53
SCHEMBL9104029 0.82 APP (0.44) APPBCHEACHEMAPK1NPSR1
Sulfuric Acid SCHEMBL9105681 0.79 CA1 (0.44) APPBCHEACHEPKMRAD52
Sulfuric Acid SCHEMBL9102371 0.78 CA1 (0.41) APPBCHEACHEPKMRAD52
Sulfuric Acid SCHEMBL9105688 0.77 CA1 (0.45) APPBCHEACHEALDH1A1PKM
Sulfuric Acid SCHEMBL9102382 0.76 CA1 (0.42) APPBCHEACHEPKMRAD52
SCHEMBL29151842 0.74 APP (0.49) APPBCHEACHEPKMRAD52
SCHEMBL9280501 0.72 MAPT (0.43) BCHELMNACYP1A2MEN1CYP2D6
SCHEMBL11508115 0.71 KCNH3 (0.47) APPBCHEACHEALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160256463-A1 NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES GALLEON PHARMACEUTICALS INC (US) 2016-09-08 US claimed
US-9351972-B2 Compounds as respiratory stimulants for treatment of breathing control disorders or diseases GALLEON PHARMACEUTICALS, INC. (US) 2016-05-31 US claimed
US-20150374706-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES GALLEON PHARMACEUTICALS, INC. 2015-12-31 US claimed
US-20140371224-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES GALLEON PHARMACEUTICALS, INC. 2014-12-18 US claimed
US-20120295911-A1 Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases GALLEON PHARMACEUTICALS, INC. 2012-11-22 US claimed
US-20120142647-A1 Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases GALLEON PHARMACEUTICALS, INC. 2012-06-07 US claimed
US-12544369-B2 Methods and pharmaceutical compositions to treat drug overdose ENALARE THERAPEUTICS INC. (US) 2026-02-10 US disclosed
US-20250325554-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS ENALARE THERAPEUTICS INC (US) 2025-10-23 US disclosed
EP-4543455-A2 METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY Enalare Therapeutics Inc. (US) 2025-04-30 EP disclosed
WO-2025080559-A1 METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE ENALARE THERAPEUTICS INC. (US) 2025-04-17 WO disclosed
US-20250114370-A1 METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE ENALARE THERAPEUTICS INC (US) 2025-04-10 US disclosed
EP-4504206-A2 RESPIRATORY STIMULANT NASAL FORMULATIONS Enalare Therapeutics Inc. (US) 2025-02-12 EP disclosed
US-20250032496-A1 METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT ENALARE THERAPEUTICS INC (US) 2025-01-30 US disclosed
US-20120295911-A1 Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases GALLEON PHARMACEUTICALS, INC. 2012-11-22 US disclosed
US-20120295911-A1 Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases GALLEON PHARMACEUTICALS, INC. 2012-11-22 US disclosed
US-20120295911-A1 Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases GALLEON PHARMACEUTICALS, INC. 2012-11-22 US disclosed
WO-2012074999-A1 NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES GALLEON PHARMACEUTICALS, INC. (US) 2012-06-07 WO disclosed
US-20120142647-A1 Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases GALLEON PHARMACEUTICALS, INC. 2012-06-07 US disclosed
US-20120142647-A1 Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases GALLEON PHARMACEUTICALS, INC. 2012-06-07 US disclosed
US-20120142647-A1 Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases GALLEON PHARMACEUTICALS, INC. 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12544369-B2 Methods and pharmaceutical compositions to treat drug overdose OPRK1, OPRD1, OPRM1 APP 2857/4885BCHE 815/4885ACHE 467/4885
US-20120142647-A1 Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases MTNR1B, CHRM3, ADRA2C APP 3078/4885BCHE 119/4885ACHE 75/4885
US-20120295911-A1 Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases PER2, SMPD4, NDUFB5 APP 2477/4885BCHE 238/4885ACHE 266/4885
US-20250325554-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS NDUFB6, NDUFB7, CHRM5 APP 4679/4885BCHE 232/4885ACHE 68/4885
US-20250032496-A1 METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT OPRK1, OPRM1, OPRD1 APP 4823/4885BCHE 564/4885ACHE 50/4885
US-20140371224-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES PER2, MTNR1B, NDUFB5 APP 2437/4885BCHE 176/4885ACHE 139/4885
US-20160256463-A1 NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES P2RX5, HRH2, ADRA2C APP 3010/4885BCHE 591/4885ACHE 407/4885
US-20250114370-A1 METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE ADRA2A, ADRA2C, OPRM1 APP 3289/4885BCHE 342/4885ACHE 29/4885
US-20150374706-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES PER2, SMPD4, NDUFB5 APP 2477/4885BCHE 238/4885ACHE 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.